Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Visani

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
British Journal of Haematology|October 4, 2005
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patientsDomenico Russo, Michele Malagola, Antonio de Vivo, et al.
European Journal of Haematology|July 19, 2008
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 casesMichele Malagola, Annalisa Peli, Daniela Damiani, et al.
British Journal of Haematology|January 16, 2007
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patientsMichele Malagola, Daniela Damiani, Giovanni Martinelli, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b TrialMarina Y Konopleva, Monique Dail, Naval G Daver, et al.
Blood|October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trialNaval G Daver, Monique Dail, Jacqueline S Garcia, et al.
The New England Journal of Medicine|December 11, 2012
Cardiovascular events and intensity of treatment in polycythemia veraRoberto Marchioli, Guido Finazzi, Giorgina Specchia, et al.
Oncotarget|November 21, 2017
The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemiaSara Galimberti, Cristina Bucelli, Elena Arrigoni, et al.
Leukemia & Lymphoma|July 13, 2011
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patientsMichele Malagola, Cristina Skert, Marco Vignetti, et al.
British Journal of Haematology|July 17, 2021
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignanciesFrancesco Passamonti, Alessandra Romano, Marco Salvini, et al.
Haematologica|October 10, 2024
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapyFederico Mosna, Erika Borlenghi, Mark Litzow, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
British Journal of Haematology|October 4, 2005
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patientsDomenico Russo, Michele Malagola, Antonio de Vivo, et al.
European Journal of Haematology|July 19, 2008
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 casesMichele Malagola, Annalisa Peli, Daniela Damiani, et al.
British Journal of Haematology|January 16, 2007
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patientsMichele Malagola, Daniela Damiani, Giovanni Martinelli, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b TrialMarina Y Konopleva, Monique Dail, Naval G Daver, et al.
Blood|October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trialNaval G Daver, Monique Dail, Jacqueline S Garcia, et al.
The New England Journal of Medicine|December 11, 2012
Cardiovascular events and intensity of treatment in polycythemia veraRoberto Marchioli, Guido Finazzi, Giorgina Specchia, et al.
Oncotarget|November 21, 2017
The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemiaSara Galimberti, Cristina Bucelli, Elena Arrigoni, et al.
Leukemia & Lymphoma|July 13, 2011
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patientsMichele Malagola, Cristina Skert, Marco Vignetti, et al.
British Journal of Haematology|July 17, 2021
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignanciesFrancesco Passamonti, Alessandra Romano, Marco Salvini, et al.
Haematologica|October 10, 2024
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapyFederico Mosna, Erika Borlenghi, Mark Litzow, et al.
Pageof 11